^
Association details:
| Biomarker: | LLGL2 underexpression + SLC7A5 underexpression |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | tamoxifen (Estrogen receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ERα-positive breast cancer
Published date:
10/03/2022
Excerpt:
As shown in Supplementary Fig. S1g,h, positive associations were found between low LLGL2 mRNA expression and longer DFS and OS in ERα-positive breast cancer patients receiving adjuvant tamoxifen therapy (P = 0.016 and P = 0.018, respectively)….As shown in Supplementary Fig. S2g, positive associations were identified between low SLC7A5 mRNA expression and longer DFS in ERα-positive breast cancer patients receiving adjuvant tamoxifen therapy (P = 0.014)....As shown in Fig. 1e,f, LLGL2low/SLC7A5low showed longer survival than LLGL2high/SLC7A5high and a positive trend of longer survival compared with other combination groups in ERα-positive breast cancer patients receiving adjuvant tamoxifen therapy.
DOI:
10.1038/s41598-022-20225-4